Sarah Davis

All publications

Journal articles

• Leaviss J, Davis S, Ren S, Hamilton J, Scope A, Booth A, Sutton A, Parry G, Buszewicz M, Moss-Morris R & White P (2020) Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. Health Technology Assessment, 24(46). View this article in WRRO
• Davis S, Simpson E, Hamilton J, James MM-S, Rawdin A, Wong R, Goka E, Gittoes N & Selby P (2020) Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technology Assessment, 24(29). View this article in WRRO
• Simpson E, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P & Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures : a systematic review and network meta-analysis. Bone, 130. View this article in WRRO
• Pandor A, Horner D, Davis S, Goodacre S, Stevens JW, Clowes M, Hunt BJ, Nokes T, Keenan J & de Wit K (2019) Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 23(63), 1-190. View this article in WRRO
• Khera TK, Burston A, Davis S, Drew S, Gooberman-Hill R, Paskins Z, Peters TJ, Tobias JH & Clark EM (2019) An observational cohort study to produce and evaluate an improved tool to screen older women with back pain for osteoporotic vertebral fractures (Vfrac): study protocol. Archives of Osteoporosis, 14(1). View this article in WRRO
• Horner D, Goodacre S, Pandor A, Nokes T, Keenan J, Hunt B, Davis S, Stevens JW & Hogg K (2019) Thromboprophylaxis in lower limb immobilisation after injury (TiLLI). Emergency Medicine Journal, 0, 1-6. View this article in WRRO
• Davis S, Goodacre S, Pandor A, Horner D, Stevens JW, Wit K & Hunt BJ (2019) Decision‐analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 186(1), 166-168. View this article in WRRO
• Davis S, Rafia R, Carroll C, Hamilton J & Essat M (2018) Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. Pharmacoeconomics. View this article in WRRO
• Julious SA, Horspool MJ, Davis S, Franklin M, Smithson WH, Norman P, Simpson RM, Elphick H, Bortolami O & Cooper C (2018) Open-label, cluster randomised controlled trial and economic evaluation of a brief letter from a GP on unscheduled medical contacts associated with the start of the school year: The PLEASANT trial. BMJ Open, 8(4). View this article in WRRO
• Rafia R, Pandor A, Davis S, Stevens JW, Harnan S, Clowes M, Sorour Y & Cutting R (2018) Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1143-1151. View this article in WRRO
• van Baal P, Morton A, Brouwer W, Meltzer D & Davis S (2017) Should cost effectiveness analyses for NICE always consider future unrelated medical costs?. BMJ, 359. View this article in WRRO
• Möller J, Davis S, Stevenson M & Caro JJ (2017) Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code. PharmacoEconomics, 35(10), 1103-1109. View this article in WRRO
• Franklin M, Davis S, Horspool M, Kua WS & Julious S (2017) Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study. PharmacoEconomics, 35(5), 561-573. View this article in WRRO
• Julious SA, Horspool MJ, Davis S, Bradburn M, Norman P, Shephard N, Cooper CL, Smithson WH, Boote J, Elphick H , Loban A et al (2016) PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term - a cluster randomised controlled trial and economic evaluation.. Health Technology Assessment, 20(93), 1-154. View this article in WRRO
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 1-406. View this article in WRRO
• Sanderson J, Martyn-St James M, Stevens J, Goka E, Wong R, Campbell F, Selby P, Gittoes N & Davis S (2016) Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone, 89, 52-58. View this article in WRRO
• Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P & Wong R (2015) Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective. PharmacoEconomics, 33(11), 1187-1194. View this article in WRRO
• Holmes M, Davis S & Simpson E (2015) Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective. PharmacoEconomics, 33(3), 225-233. View this article in WRRO
• Pennington B & Davis S (2014) Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. Value in Health, 17(8), 762-771. View this article in WRRO
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M & Taylor RS (2014) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care, 30(3), 312-324. View this article in WRRO
• Akunne A, Davis S, Westby M & Young J (2014) The cost-effectiveness of multi-component interventions to prevent delirium in older people undergoing surgical repair of hip fracture.. Eur J Orthop Surg Traumatol, 24(2), 187-195.
• (2014) Correction. Heart, 100(4), 350-350.
• Horspool MJ, Julious SA, Boote J, Bradburn MJ, Cooper CL, Davis S, Elphick H, Norman P, Smithson WH & vanStaa T (2013) Preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT): Study protocol for a cluster randomised control trial. Trials, 14(1). View this article in WRRO
• Tosh J, Archer R, Davis S, Stevenson M & Stevens JW (2013) Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.. Pharmacoeconomics, 31(8), 653-661.
• Davis S & Wailoo A (2013) A review of the psychometric performance of the EQ-5D in people with urinary incontinence.. Health Qual Life Outcomes, 11, 20. View this article in WRRO
• Petkar S, Bullock I, Davis S & Cooper P (2013) Transient loss of consciousness: Summary of NICE guidance. Heart.
• Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P & Moxham T (2013) Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.. Age Ageing, 42(1), 14-20.
• Davis S, Westby M, Petkar S & Pitcher D (2013) Tilt testing is more cost-effective than implantable loop recorder monitoring as a means of directing pacing therapy in people with recurrent episodes of suspected vasovagal syncope that affect their quality of life or present a high risk of injury.. Heart, 99(11), 805-810.
• Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A , Jeffreys M et al (2012) The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.. Health Technol Assess, 16(21), 1-470.
• Davis S, Westby M, Pitcher D & Petkar S (2012) Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained.. Europace, 14(3), 402-409.
• Westby M, Bullock I, Cooper PN, Davis S & Guideline Dev Grp (2010) Guidelines Transient loss of consciousness-initial assessment, diagnosis, and specialist referral: summary of NICE guidance. BRIT MED J, 341.
• Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S , Chisholm I et al (2008) A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.. Health Technol Assess, 12(27), iii-124.
• Bansback N, Davis S & Brazier J (2007) Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.. Eye (Lond), 21(12), 1455-1463.
• Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 11(7).
• Stevenson M, Davis S, Lloyd-Jones M & Beverley C (2007) The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.. Health Technol Assess, 11(4), 1-134.
• Ward S, Simpson E, Davis S, Hind D, Rees A & Wilkinson A (2007) Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.. Health Technol Assess, 11(40), 1-144.
• Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health Technol Assess, 11(7), iii-231.
• Brennan A, Akehurst R, Davis S, Sakai H & Abbott V (2007) The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.. Value Health, 10(1), 32-41.
• Stevenson M, Davis S & Kanis J (2006) The hospitalisation costs and out-patient costs of fragility fractures. Women's Health Medicine, 3(4), 149-151.
• Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S & Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.. Health Technol Assess, 9(22), 1-160. View this article in WRRO
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al () Corrigendum: A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 407-424. View this article in WRRO
• Campbell F, Holmes M, Everson-Hock E, Davis S, Buckley Woods H, Anokye N, Tappenden P & Kaltenthaler E () A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. Health Technology Assessment, 19(60), 1-110. View this article in WRRO

Conference proceedings papers

• Elphick H, Horspool M, Davis S, Bradburn M, Norman P, Shephard N, Cooper C, Smithson WH, Boote J, Loban A , Franklin M et al (2016) LATE-BREAKING ABSTRACT: PLEASANT: Preventing and lessening exacerbations of asthma in school-age children associated with a new term. 1.6 General Practice and Primary Care
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad E, Buyse M & Taylor R (2013) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMOURS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
• Brennan A, Wilson R, Davis S, Brandtmuller A & Akehurst R (2007) Economic evaluation of the use of lanthanum carbonate from an Australian perspective. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 22 (pp 186-186)
• Brennan A, Akehurst R, Davis S & Sakai H (2004) Lanthanum carbonate for the treatment of hyperphosphataemia: Development of a cost effectiveness model. VALUE HEALTH, Vol. 7(6) (pp 805-805)

Reports

• Kua WS & Davis S (2016) Systematic Review of Health State Utilities in Children with Asthma View this article in WRRO